GlaxoSmithKline PLC at Citi BioPharma Conference (Virtual) Transcript
Welcome back. Delighted to introduce our next session today. We have Hal Barron, the Chief Scientific Officer at GSK. We've got Jeff McLaughlin and other members of the GSK Investor Relation team. Pleasure to have you with us, Hal.
Questions & Answers
So look, I'm looking forward to a broad-ranging conversation. Given GSK is one of the preeminent vaccine manufacturers in the world and given we had news overnight of the suspension of one of your competitors' Phase III trial programs for COVID, as a way of segmenting into your COVID efforts, perhaps you can talk to how you would see the hurdle for safety to COVID. And I guess, general concept, because, obviously, we don't know the details and there's been some information that trial may restart. How many episodes of demyelination associated with a vaccine in a patient without preexisting conditions is enough to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
